Yoon Hang Kim, MD, MPH

Board-Certified in Preventive Medicine | Integrative & Functional Medicine Physician

What this article is — and is not. This is a hypothesis. It proposes a biologically plausible, testable model in which low-dose naltrexone (LDN) might indirectly influence purinergic “cell danger” signaling and, in turn, inflammation-driven suppression of the hypothalamic-pituitary-gonadal (HPG) axis. It is not a claim of proven mechanism, and it is not clinical advice. No published study has shown that LDN acts on purinergic receptors, extracellular ATP, or the Cell Danger Response, nor that it restores testosterone in this setting. Each section below is labeled by evidence tier so the reader always knows whether a statement is established biology, a proposed model, or an unproven hypothesis.

1. A Clinical Observation That Prompts the Question

EVIDENCE TIER — The observation is real; its interpretation is not established.

Consider an individual whose laboratory trajectory over roughly a year shows a high-sensitivity interleukin-6 (IL-6) that has risen substantially while remaining near the upper end of its reference range, a tumor necrosis factor-alpha (TNF-α) sitting at the upper-normal (borderline) limit, and a free testosterone that has declined meaningfully over the same window. Two honest caveats belong up front. First, classified qualitatively, the inflammatory markers are best described as upper-normal and trending upward rather than frankly high — the potential signal is the trajectory, not the magnitude, which is precisely what “subclinical” denotes. Second, a single individual’s longitudinal pattern cannot establish causation: age, adiposity, sleep, stress, and assay drift all remain unexcluded. The pattern is best treated as a question generator, not evidence for any mechanism.

2. Established Ground: Inflammatory Cytokines Suppress the HPG Axis

EVIDENCE TIER — Established (human, animal, and in-vitro evidence across multiple laboratories).

That chronic pro-inflammatory signaling can suppress gonadal function is well supported. Cytokines act centrally, blunting gonadotropin-releasing hormone (GnRH) and luteinizing hormone (LH) pulsatility, and peripherally, at the testicular Leydig cell [1]. TNF-α is the most clearly established direct suppressor of Leydig steroidogenesis: intratesticular TNF-α rapidly downregulates steroidogenic acute regulatory (StAR) protein and testosterone biosynthesis [3], and a separate mechanism proceeds through induction of the transcriptional repressor DAX-1 [4].

A precision point that matters for honest citation: in a TM3 Leydig-cell model, TNF-α produced a robust dose-dependent fall in testosterone, whereas IL-6 and IL-1β had only a subtle (though significant) direct effect on testosterone, with their larger effect on progesterone [2]. And in the intratesticular in-vivo study above, IL-1β did not reduce serum testosterone or StAR [3]. So the accurate statement is that TNF-α is a strong direct Leydig suppressor, while IL-6’s contribution is real but likely more central/indirect — not that “IL-6 strongly lowers testosterone at the Leydig cell.”

Taken together, the direction of effect — rising inflammatory tone accompanying falling androgen output — is consistent with well-characterized biology [1–4]. What remains not established is the upstream question this article is really about: what is driving the inflammatory tone, and whether it can be interrupted.

3. Established Ground: The Purinergic Inflammatory Amplifier

EVIDENCE TIER — Established (well-replicated receptor and inflammasome biology).

Extracellular ATP (eATP) is a canonical danger signal. Released by stressed or damaged cells, it gates the P2X7 receptor on macrophages, microglia, and neutrophils, driving potassium efflux, NLRP3 inflammasome assembly, caspase-1 activation, and the release of mature IL-1β — which in turn amplifies IL-6 and TNF-α [5]. This eATP–P2X7–NLRP3–IL-1β axis is one of the better-characterized routes by which a persistent “danger” stimulus can sustain a self-reinforcing inflammatory loop [5].

4. A Framework, Not a Diagnosis: The Cell Danger Response

EVIDENCE TIER — Proposed model (influential, biologically grounded, but not a validated clinical entity).

The Cell Danger Response (CDR), formulated by Robert K. Naviaux, MD, PhD, proposes that cells enter an evolutionarily conserved, mitochondria-coordinated defensive state whose first wave is sustained by purinergic signaling — the release of eATP and related metabolites [6]. In the model, once the threat resolves, a choreographed sequence reverses the CDR and permits healing; when the response fails to terminate, the model holds that whole-body metabolism is disturbed and chronic disease can follow [6,7,8].

It is important to be clear about the epistemic status here. The CDR is a hypothesis-generating framework, not a diagnosis with validated criteria or a directly measurable clinical state. Antipurinergic strategies have shown effects in animal models and only limited early human data [6]. Describing a person as being “in a chronic CDR” is therefore a model-based interpretation, not an established finding.

5. Established Ground: What Low-Dose Naltrexone Actually Does

EVIDENCE TIER — Receptor-level actions: established in vitro/animal. Human clinical effect: preliminary (small trials).

Low-dose naltrexone (typically 1–4.5 mg/day) has two reasonably characterized non-addiction actions. First, independent of classical opioid-receptor blockade, it antagonizes Toll-like receptor 4 (TLR4) on microglia and macrophages, dampening NF-κB-driven output of TNF-α, IL-1β, and IL-6 [9,10]. Second, brief daily opioid-receptor blockade upregulates the opioid growth factor (OGF, [Met⁵]-enkephalin)–OGF receptor (OGFr) axis, a tonic regulator of cell proliferation and tissue homeostasis [11,12].

A correction worth making explicitly, because it is often mis-stated: the ultra-low-dose naltrexone (ULDN, <1 µg/day) mechanism described in the peer-reviewed literature is binding to filamin A, a scaffolding protein involved in µ-opioid receptor signaling — not an “adenosine crosstalk” pathway [10]. There is a separate, older observation that chronic naltrexone can alter adenosine-receptor density in rodent brain, but that is an adaptive expression change in animals, not an established ULDN signaling mechanism and not a demonstrated link to purinergic-CDR biology.

On human anti-inflammatory effect, the most direct data come from a small fibromyalgia pilot in which eight weeks of LDN was associated with reduced plasma IL-6, TNF-α, IL-1β, and other cytokines [13]. This is genuinely relevant — it touches the very cytokines implicated in HPG suppression — but it must be reported with its limits: n = 8, single-blind, no true placebo dose administered, and individuals with overt inflammation excluded. It is suggestive, not confirmatory.

For balance, a mechanistic caution: a controlled rodent study found LDN’s reported benefits appear independent of the proopiomelanocortin/β-endorphin system, and concluded that a compelling unifying mechanism for LDN is still lacking [14]. In other words, even LDN’s own mechanism is incompletely settled.

6. The Hypothesis (the central claim of this article)

EVIDENCE TIER — Unproven hypothesis. No direct evidence exists. Presented as a testable model only.

Statement of the hypothesis. LDN does not bind purinergic receptors, does not measurably alter extracellular ATP, and has never been shown to modify the Cell Danger Response. No study has measured eATP, P2X7 activity, or CDR markers before and after LDN. The proposed link is therefore inferential and convergent: LDN’s established target (TLR4) and the purinergic amplifier (P2X7) both feed the same downstream node — NF-κB / NLRP3 / IL-6–TNF-α. The hypothesis is that by lowering the TLR4-driven priming signal that P2X7 subsequently amplifies, LDN might indirectly attenuate a persistent, purinergically sustained inflammatory loop, and thereby relieve some of the cytokine-mediated pressure on the HPG axis.

Two things must stay explicitly hypothetical. (a) The mechanism: convergence on a shared signaling node is a reasonable, falsifiable idea — it is not a demonstrated pathway. (b) The clinical payoff: that interrupting this loop with LDN would raise free testosterone or restore HPG competence has never been tested in any trial. Both remain open questions, not conclusions.

7. How This Hypothesis Could Be Tested — or Falsified

EVIDENCE TIER — Methodological (what evidence would move the hypothesis toward or away from support).

A hypothesis earns its keep by being falsifiable. Predictions that would follow if the model were correct include: in individuals with subclinical inflammatory drift, a course of LDN should measurably lower IL-6/TNF-α (partially supported by preliminary data [13]); if a purinergic loop is truly upstream, markers reflecting eATP/P2X7–inflammasome activity should also move; and any recovery in free testosterone should track the fall in inflammatory tone rather than precede it. The cleanest test would be a prospective, controlled study measuring inflammatory cytokines, an index of purinergic/inflammasome activity, and gonadal hormones before and after LDN. Absent that, the hypothesis remains unconfirmed — and a null cytokine or hormone result would count against it.

8. Honest Limitations

EVIDENCE TIER — Summary of what this article cannot claim.

• No direct evidence links LDN or ULDN to purinergic receptors, eATP, or the CDR.

• The Cell Danger Response is a model, not a validated, measurable diagnosis.

• The motivating laboratory pattern is a single-individual trajectory in a near-normal range; it cannot establish causation.

• Human LDN anti-inflammatory data rest on small trials; LDN’s own mechanism is not fully settled.

• IL-6’s direct Leydig-cell effect is modest; TNF-α carries the stronger established peripheral signal.

9. What This Means in Practice

Nothing in this article should be read as a recommendation to prescribe or take LDN for inflammation, the CDR, or low testosterone. Its purpose is to frame a coherent, testable question at the intersection of purinergic biology, chronic subclinical inflammation, and HPG-axis physiology — and to be explicit that the central claim is a hypothesis awaiting evidence. Decisions about evaluation or treatment belong in an individualized clinical relationship. Educational questions about integrative and functional approaches to complex chronic illness are welcome through www.directintegrativecare.com.

About Dr. Kim

Yoon Hang “John” Kim, MD, MPH is board-certified in Preventive Medicine and in Integrative & Holistic Medicine, and practices Integrative & Functional Medicine. He trained as an Osher Fellow in Integrative Medicine under Dr. Andrew Weil at the University of Arizona, holds medical acupuncture certification through UCLA, and has helped establish integrative medicine programs at academic medical centers. He writes on low-dose naltrexone, complex chronic illness, and the intersection of conventional and functional medicine. Learn more at www.directintegrativecare.com.

Editorial note: this piece presents a hypothesis for discussion and does not constitute medical advice. (Replace this About section with your canonical block as needed.)

References

All references below were verified against PubMed and the publisher of record. DOI links are clickable.

1. Ma Y, Fan X, Han J, Cheng Y, Zhao J, Fang W, Gao L. Critical illness and sex hormones: response and impact of the hypothalamic–pituitary–gonadal axis. Ther Adv Endocrinol Metab. 2025;16:20420188251328192. PMID 40183031. doi.org/10.1177/20420188251328192

2. Leisegang K, Henkel R. The in vitro modulation of steroidogenesis by inflammatory cytokines and insulin in TM3 Leydig cells. Reprod Biol Endocrinol. 2018;16(1):26. PMID 29566712. doi.org/10.1186/s12958-018-0341-2

3. Morales V, Santana P, Díaz R, Tabraue C, Gallardo G, López Blanco F, Hernández I, Fanjul LF, Ruiz de Galarreta CM. Intratesticular delivery of tumor necrosis factor-α and ceramide directly abrogates steroidogenic acute regulatory protein expression and Leydig cell steroidogenesis in adult rats. Endocrinology. 2003;144(11):4763–4772. PMID 12959973. doi.org/10.1210/en.2003-0569

4. Sadasivam M, Ramatchandirin B, Balakrishnan S, Prahalathan C. TNF-α-mediated suppression of Leydig cell steroidogenesis involves DAX-1. Inflamm Res. 2015;64(7):549–556. doi.org/10.1007/s00011-015-0835-8

5. Ren WJ, Illes P. Involvement of P2X7 receptors in chronic pain disorders. Purinergic Signal. 2022;18(1):83–92. PMID 34799827. doi.org/10.1007/s11302-021-09796-5

6. Naviaux RK. Metabolic features of the cell danger response. Mitochondrion. 2014;16:7–17. PMID 23981537. doi.org/10.1016/j.mito.2013.08.006

7. Naviaux RK. Metabolic features and regulation of the healing cycle—A new model for chronic disease pathogenesis and treatment. Mitochondrion. 2019;46:278–297. PMID 30099222. doi.org/10.1016/j.mito.2018.08.001

8. Naviaux RK. Cell danger response biology—the new science that connects environmental health with mitochondria and the rising tide of chronic illness. Mitochondrion. 2020;51:40–45. doi.org/10.1016/j.mito.2019.12.005

9. Younger J, Parkitny L, McLain D. The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain. Clin Rheumatol. 2014;33(4):451–459. PMID 24526250. doi.org/10.1007/s10067-014-2517-2

10. Toljan K, Vrooman B. Low-dose naltrexone (LDN)—review of therapeutic utilization. Med Sci (Basel). 2018;6(4):82. PMID 30248938. doi.org/10.3390/medsci6040082

11. Donahue RN, McLaughlin PJ, Zagon IS. Low-dose naltrexone targets the opioid growth factor–opioid growth factor receptor pathway to inhibit cell proliferation: mechanistic evidence from a tissue culture model. Exp Biol Med (Maywood). 2011;236(9):1036–1050. PMID 21807817. doi.org/10.1258/ebm.2011.011121

12. Donahue RN, McLaughlin PJ, Zagon IS. The opioid growth factor (OGF) and low dose naltrexone (LDN) suppress human ovarian cancer progression in mice. Gynecol Oncol. 2011;122(2):382–388. PMID 21531450. doi.org/10.1016/j.ygyno.2011.04.009

13. Parkitny L, Younger J. Reduced pro-inflammatory cytokines after eight weeks of low-dose naltrexone for fibromyalgia. Biomedicines. 2017;5(2):16. PMCID PMC5489802. doi.org/10.3390/biomedicines5020016

14. Metz MJ, Daimon CM, Hentges ST. Reported benefits of low-dose naltrexone appear to be independent of the endogenous opioid system involving proopiomelanocortin neurons and β-endorphin. eNeuro. 2021;8(3):ENEURO.0087-21.2021. PMID 34031099. doi.org/10.1523/ENEURO.0087-21.2021